AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01813890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Description: Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
Study NCT01813890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Description: Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
Study NCT01813890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
Study NCT01602055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Single dose 500 mg of film coated tablet
Study NCT01602055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Single dose 500 mg of film coated tablet
Study NCT05708807 — intervention group
Intervention type: OTHER
Intervention: Observational - all
Description: All stroke patients are included.
Study NCT04186455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: proseal
Description: laryngeal mask proseal
Study NCT04186455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: baska-mask
Description: laryngeal mask baska-mask
Study NCT03892161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg tablet
Description: Standard dose DRV/r administered
Study NCT03892161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin 600mg QD tablet and DTG 50mg BD
Description: Rifampicin and DTG added
Study NCT03426098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secret RF
Description: A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
Study NCT00243997 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Becoming Parents Program
Description: Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
Study NCT00243997 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Becoming Parents Program
Description: Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg, twice daily, 28 days
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 15 mg twice daily, 28 days
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 50 mg twice daily, 28 days
Study NCT00448175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgent PC Neuromodulation System
Description: The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
Study NCT00448175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 150 mg twice daily, 28 days
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, 300 mg twice daily, 28 days
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 5, 28 days
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 6, 28 days
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 7, 28 days
Study NCT03538743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Tablet, dose TBD, twice daily, Cohort 8, 28 days
Study NCT04207047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genius
Description: The Infini Radiofrequency System (K121481) is the predicate device. It is a minimally invasive radiofrequency device that employs a bipolar microneedle electrode system indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of facial wrinkles.~The Genius system is substantially equivalent to the Infini device with a digitally controlled direct drive mechanism for needle insertion and an improved needle design for easier needle insertion. The active tip of the Genius system is the substantially equivalent to the Infini device. The handpiece of the Genius system has also been redesigned to be lighter and more ergonomic.
Study NCT04207047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eC02
Description: The eCO2 Laser System (K091115) is indicated for use in dermatological procedures requiring ablation (removal), resurfacing and coagulation of soft tissue. Additionally, the 120 micron and 300 micron spot sizes are used in the treatment of wrinkles; rhytides, furrows, fine lines, textural irregularities, pigmented lesions and vascular dyschromia. The fractional 90 degree BellaV handpiece is intended to provide fractional CO2 treatment of skin and is not yet cleared.
Study NCT04207047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoPlus
Description: The PICOPLUS Laser System (K173700) is indicated for use in surgical and aesthetic applications in the medical specialties of dermatology and general and plastic surgery as follows:
Study NCT04207047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LaseMD
Description: The LaseMD Laser System (K171009) is a 1927 factional thulium laser indicated for use in dermatological procedures requiring the coagulation of soft tissue, treatment of actinic keratosis, and treatment of benign pigmented lesions such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and ephiledes (freckles). The cleared LaseMD system is a 5W system.
Study NCT04207047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LaseMD Flex
Description: There are two new versions of the LaseMD system to be used in this study that are uncleared and investigational use only. The only change from the cleared system to the one of the LaseMD systems to be used in this study is that the watts have been increased to 20W and a new tip configuration with a larger 250+ um spot size. The other LaseMD system to be used in this study is the LaseMD FLEX. It also has 20W with larger spot size, a modified flat-top beam profile (as opposed to a Gaussian beam profile) and a faster scan rate. All other technical specifications remain the same as the cleared device.
Study NCT00421330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Aneurysm Repair
Study NCT00421330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair
Study NCT01758510 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HYNR-CS-Allo
Description: The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10\^6 cells/kg, 0.5 X 10\^6 cells/kg, 1 X 10\^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10\^6 cells/kg dose cohort.
Study NCT01902979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study NCT04707755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery technique
Description: The patient will sit on chair in a quiet room. The patients will be observing motor performance in video, motor performance video will consist of (1) knee flexion and extension movement, (2) sitting to standing movement, (3) stepping movement, (4) walking, (5) climbing and descending stairs.~Addition to motor imagery, the patients will be provided the passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
Study NCT04707755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: It includes passive stretching, ROM exercises, sitting to standing, anteroposterior step, climbing and descending stairs.
Study NCT01629615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
Study NCT03952260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting time for clear fluid prior to anaesthesia
Description: This study is to evaluate the latest fasting protocol that is currently adopted and recommended by United Kingdom, France and Royal Children Hospital Melbourne.~The research question is should we change our fasting protocol for paediatric patients prior to operation The anaesthesia service is being studied. Prior to induction, the amount of abdominal contents was examined using ultrasound scan. In addition, parents will complete a questionnaire after the surgery to assess anxiety level of patients before and after the surgery.
Study NCT03623867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
Study NCT03623867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will take placebo once weekly in week 0-4, and once monthly till week 48
Study NCT02809066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sufficient dietary calcium intake in premenstrual syndrome
Description: Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~* 50 gr kashkaval cheese,~* 400 ml milk and~* 150 gr yogurt for each day.
Study NCT00891826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (EPAX 6015 TG)
Description: The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
Study NCT00891826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil
Description: The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
Study NCT03633357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-18038683
Description: JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days.
Study NCT03633357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-18038683
Description: JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days.
Study NCT03633357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will take two placebo tablets daily, for seven days.
Study NCT03633357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take two placebo tablets daily, for seven days.
Study NCT02808104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mazindol
Study NCT02808104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mazindol
Study NCT00544921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLY-230
Study NCT00544921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug administered
Study NCT02257424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trametinib 2 mg daily
Study NCT02257424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hydroxychloroquine (HCQ)
Description: hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
Study NCT02257424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dabrafenib 150 mg orally twice a day
Study NCT03128957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVOS cerebral oximeter
Description: Measuring percutaneous cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
Study NCT03128957 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Licox cerebral oxygenation monitor
Description: Measuring tissue cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
Study NCT03128957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral oxygenation
Description: Measuring cerebral oxygenation with varying ventilation strategy
Study NCT03665038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Administered as IV infusion.
Study NCT03042000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-NCRT
Description: without the preoperative concurrent chemoradiothearpy (no neoadjuvant chemoradiation)
Study NCT03042000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NCRT
Description: the preoperative concurrent chemoradiothearpy (neoadjuvant chemoradiation)
Study NCT03042000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine with oxaliplatin
Description: combined chemotherapy with capecitabine with oxaliplatin
Study NCT03042000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: single-agent chemotherapy with capecitabine
Study NCT03042000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEM
Description: transanal endoscopic microsurgery (TEM) excision of the lesion
Study NCT03042000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical resection
Description: radical resection of rectal cancer
Study NCT01291017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD0332991
Description: PD0332991 125 mg PO days 1 - 21
Study NCT05539846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified blood collection method
Description: The bevel of the needle head of the blood collection needle was downward, and the needle was inserted into the skin with the bevel of the needle parallel to the skin.
Study NCT03998657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Prostate Treatment
Description: The Exablate system is a non-invasive thermal ablation device that is being used to ablate tissue. The system combines a focused ultrasound surgery (FUS) delivery system and MRI scanner.
Study NCT01966770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 1 (ocufilcon D / ocufilcon D)
Description: Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
Study NCT01966770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 2 (ocufilcon D / enfilcon A)
Description: Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
Study NCT01966770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 3 (ocufilcon D / comfilcon A)
Description: Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
Study NCT01966770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 4 (methafilcon A / methafilcon A)
Description: Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
Study NCT01966770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 5 (methafilcon A / comfilcon A)
Description: Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
Study NCT01966770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pair 6 (omafilcon A / comfilcon A)
Description: Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
Study NCT00392184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation
Study NCT03075085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WISE (We Inspire Smart Eating)
Description: An enhanced implementation strategy for evidence-based obesity prevention in childcare
Study NCT03075085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISE (We Inspire Smart Eating)
Description: An enhanced implementation strategy for evidence-based obesity prevention in childcare
Study NCT00542997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
Description: IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
Study NCT02326519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intracardiac electrode catheter
Description: All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
Study NCT04133584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 +SIV
Description: Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.
Study NCT04133584 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EV71
Description: Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last
Study NCT04133584 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SIV
Description: Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
Study NCT04183985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty prosthesis
Description: In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
Study NCT04183985 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty prosthesis
Description: In patients undergoing same-day bilateral total knee arthroplasty, after deciding the implant of TKA(anatomically aligned TKA implant or conventaional TKA implant) using random number table, compare the result of clinical outcome about two instruments.
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study.
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Description: An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate
Description: An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: 1.5 mg/kg IV daily on Day 0-3.~(standard of care)
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rATG
Description: 1.5 mg/kg IV daily on Day 0-3.~(standard of care)
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)
Study NCT02152345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)
Study NCT02152345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal transplant
Description: Standard organ transplant of a kidney into a patient with end-stage renal disease.
Study NCT02152345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal transplant
Description: Standard organ transplant of a kidney into a patient with end-stage renal disease.